VivoSeq
Ophthalmology

Neovascular Glaucoma

6

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

Neovascular Glaucoma is an early-stage landscape with 6 programs across 4 companies. The most active players are Bayer, Regeneron, Roche. 1 therapy is approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

82/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 3Regeneron logo

Regeneron

1 program

Phase 3Roche logo

Roche

3 programs

ApprovedNovartis logo

Novartis

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

7programs
Small molecule457%
Monoclonal antibody229%
Protein / enzyme114%

Modality classified for 100% of 7 pipeline programs.

Analysis

Trial Status

14

clinical trials

Completed9 · 64%
Withdrawn2 · 14%
Active, not recruiting1 · 7%
Unknown status1 · 7%
Recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

Drug Use Investigation for Eylea for Neovascular Glaucoma (NVG)
Recruiting·Bayer logoBayer·N/A·NCT04519619·480 enrolled
KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial
Active, not recruiting·SSun Yat-sen University·Phase 1·NCT04844619·40 enrolled
Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma
Completed·UUniversity of Luebeck·N/A·NCT01370135·20 enrolled
Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients
Completed·Bayer logoBayer·Phase 3·NCT02396316·54 enrolled
Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma
Completed·SSiriraj Hospital·Phase 4·NCT01922154·15 enrolled
Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma
Completed·RRuijin Hospital·Phase 4·NCT02647515·18 enrolled
Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma
Completed·—·Phase 3·NCT03172299·57 enrolled
Intravitreal Bevacizumab for Neovascular Glaucoma
Completed·SShahid Beheshti University of Medical Sciences·N/A·NCT00384631·26 enrolled
Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma
Completed·UUniversity of Colorado, Denver·N/A·NCT01711879·7 enrolled
Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied
Completed·Bayer logoBayer·Phase 3·NCT03639675·16 enrolled
Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
Completed·SSiriraj Hospital·N/A·NCT04970251·5 enrolled
Effects of Travoprost on Neovascular Glaucoma
Withdrawn·FFederal University of São Paulo·N/A·NCT00441181·40 enrolled
Lucentis for New Onset Neovascular Glaucoma
Withdrawn·UUniversity of Illinois at Chicago·Phase 1/2·NCT00727038
Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study
Unknown status·LLEANDRO CABRAL ZACHARIAS·Phase 3·NCT02914626·28 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)